BCL2: A Potential Drug Target and Biomarker (G11177)

Target Name: BAZ1A

NCBI ID: G11177

BAZ1A

BCL2: A Potential Drug Target and Biomarker

BAZ1A, also known as BAZ1A_HUMAN, is a gene that has been identified as a potential drug target or biomarker for various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. The gene is located on chromosome 6 and encodes for a protein known as BCL2 (B cell lymphoma 2), which is a protein that plays a critical role in regulating the survival and proliferation of cancer cells.

Studies have shown that BCL2 is highly expressed in various types of cancer, including breast, lung, and ovarian cancer. It has also been implicated in the development of neurodegenerative disorders, such as Alzheimer's disease and Parkinson's disease. In addition, BCL2 has been linked to autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis.

One of the main reasons for the interest in BCL2 and its potential as a drug target is its ability to interact with multiple signaling pathways. BCL2 has been shown to interact with several signaling pathways, including the PI3K/Akt signaling pathway, the TGF-β signaling pathway, and the NF-kappa-B signaling pathway. These interactions make BCL2 a potential target for small molecules that can inhibit its activity.

One of the most promising compounds that have been shown to interact with BCL2 is called BHQ-1402. BHQ-1402 is a small molecule that is currently being investigated as a potential treatment for various diseases, including cancer. Studies have shown that BHQ-1402 is able to inhibit the activity of BCL2, leading to the collapse of its signaling pathway and the inhibition of its growth and proliferation.

Another promising compound that has been shown to interact with BCL2 is called R121-84. R121-84 is a small molecule that is being investigated as a potential treatment for various diseases, including neurodegenerative disorders. Studies have shown that R121-84 is able to inhibit the activity of BCL2, leading to the inhibition of its growth and proliferation.

In addition to its potential as a drug target, BCL2 is also of interest as a biomarker. The expression of BCL2 has been shown to be elevated in various types of cancer, including breast, lung, and ovarian cancer. This suggests that BCL2 may be a useful biomarker for the diagnosis and prognosis of these diseases.

Furthermore, BCL2 has also been implicated in the development of neurodegenerative disorders. Studies have shown that BCL2 is highly expressed in the brains of individuals with Alzheimer's disease, and that its expression is associated with the progression of the disease. This suggests that BCL2 may be a potential target for the development of neurodegenerative disorders.

In conclusion, BCL2 is a gene that has been identified as a potential drug target or biomarker for various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. Its ability to interact with multiple signaling pathways makes it a promising target for small molecules that can inhibit its activity. The development of small molecules that can inhibit the activity of BCL2 is a promising area of research that may lead to the development of new treatments for a variety of diseases.

Protein Name: Bromodomain Adjacent To Zinc Finger Domain 1A

Functions: Regulatory subunit of the ATP-dependent ACF-1 and ACF-5 ISWI chromatin remodeling complexes, which form ordered nucleosome arrays on chromatin and slide edge- and center-positioned histone octamers away from their original location on the DNA template to facilitate access to DNA during DNA-templated processes such as DNA replication, transcription, and repair (PubMed:17099699, PubMed:28801535). Both complexes regulate the spacing of nucleosomes along the chromatin and have the ability to slide mononucleosomes to the center of a DNA template in an ATP-dependent manner (PubMed:14759371, PubMed:17099699, PubMed:28801535). The ACF-1 ISWI chromatin remodeling complex has a lower ATP hydrolysis rate than the ACF-5 ISWI chromatin remodeling complex (PubMed:28801535). Has a role in sensing the length of DNA which flank nucleosomes, which modulates the nucleosome spacing activity of the ACF-5 ISWI chromatin remodeling complex (PubMed:17099699). Involved in DNA replication and together with SMARCA5/SNF2H is required for replication of pericentric heterochromatin in S-phase (PubMed:12434153). May have a role in nuclear receptor-mediated transcription repression (PubMed:17519354)

The "BAZ1A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about BAZ1A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets